Evidence map›Paper›PMID 26721894›Full record

ArticleHaematologica2016

Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells.

Loredana Ruggeri, Elena Urbani, Pascale André, Antonella Mancusi, Antonella Tosti, Fabiana Topini, Mathieu Bléry, Lucia Animobono, François Romagné, Nicolai Wagtmann and 1 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02921685 (A Phase 1 Study of MONALIZUMAB), which is not on this map. Cited by 93 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02921685 phase1unknown statusnot on this map

A Phase 1 Study of MONALIZUMAB (IPH2201), a Humanized Anti CD94/NKG2A Monoclonal Antibody (Mab) Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation (SCT) Prepared With a Reduced Intensity Conditioning

TypeinterventionalSponsorInstitut Paoli-CalmettesRan2016 to 2020Enrolled18ConditionsHematologic MalignanciesArmsMonalizumab
3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 1 synthesis or guideline pooled it, 152 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Harnessing Immune Response in Acute Myeloid Leukemia.Journal of clinical medicine · 2023
    Review
  19. Article
  20. Article

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Loredana RuggeriDivision of Hematology and Clinical Immunology and Bone Marrow Transplantation Program, Department of Medicine, University of Perugia, Italy loredana.ruggeri@unipg.it.
Elena UrbaniDivision of Hematology and Clinical Immunology and Bone Marrow Transplantation Program, Department of Medicine, University of Perugia, Italy.
Pascale AndréInnate Pharma, Marseille, France.
Antonella MancusiDivision of Hematology and Clinical Immunology and Bone Marrow Transplantation Program, Department of Medicine, University of Perugia, Italy.
Antonella TostiDivision of Hematology and Clinical Immunology and Bone Marrow Transplantation Program, Department of Medicine, University of Perugia, Italy.
Fabiana TopiniDivision of Hematology and Clinical Immunology and Bone Marrow Transplantation Program, Department of Medicine, University of Perugia, Italy.
Mathieu BléryInnate Pharma, Marseille, France.
Lucia AnimobonoDivision of Hematology and Clinical Immunology and Bone Marrow Transplantation Program, Department of Medicine, University of Perugia, Italy.
François RomagnéDivision of Immunology, University of Marseille, France.
Nicolai WagtmannInnate Pharma, Marseille, France.
Andrea VelardiDivision of Hematology and Clinical Immunology and Bone Marrow Transplantation Program, Department of Medicine, University of Perugia, Italy.
University of Perugia · ITInnate Pharma (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer cells are key cells of the innate immune system. Natural killer cell receptor repertoires are diversified by a stochastic expression of killer-cell-immunoglobulin-like receptors and lectin-like receptors such as NKG2 receptors. All individuals harbor a subset of natural killer cells expressing NKG2A, the inhibitory checkpoint receptor for HLA-E. Most neoplastic and normal hematopoietic cells express HLA-E, the inhibitory ligand of NKG2A. A novel anti-human NKG2A antibody induced tumor cell death, suggesting that the antibody could be useful in the treatment of cancers expressing HLA-E. We found that immunodeficient mice, co-infused with human primary leukemia or Epstein-Barr virus cell lines and NKG2A(+) natural killer cells, pre-treated with anti-human NKG2A, were rescued from disease progression. Human NKG2A(+) natural killer cells reconstituted in immunodeficient mice after transplantation of human CD34(+) cells. These natural killer cells are able to kill engrafted human primary leukemia or Epstein-Barr virus cell lines by lysis after intraperitoneal administration of anti-human NKG2A. Thus, this anti-NKG2A may exploit the anti-leukemic action of the wave of NKG2A(+) natural killer cells recovering after hematopoietic stem cell transplants or adoptive therapy with natural killer cell infusions from matched or mismatched family donors after chemotherapy for acute leukemia, without the need to search for a natural killer cell alloreactive donor.

Indexed as

AnimalsAntibodies, MonoclonalBone Marrow CellsCell Line, TransformedCytotoxicity, ImmunologicDisease Models, AnimalFemaleHistocompatibility Antigens Class IHLA-E AntigensHumansKiller Cells, NaturalLeukemiaLymphocyte ActivationLymphocyte DepletionMiceNK Cell Lectin-Like Receptor Subfamily CAntibodies, MonoclonalHistocompatibility Antigens Class IHLA-E AntigensNK Cell Lectin-Like Receptor Subfamily C

Identifiers

PMID26721894
PMCPMC5004363
OpenAlexW2201929875

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.